Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Clinical trial NCT06957379 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06957379
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-29
- Primary completion
- 2025-06-01
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.